促红细胞生成素及其受体在非小细胞肺癌中的表达及其与微血管密度的相关性

Expression of erythropoietin and erythropoietin receptor in non-small cell lung cancer and its correlation with microvessel density

目的探讨非小细胞肺癌（NSCLC）组织中促红细胞生成素（EPO）及其受体（EPO—R）的表达，及其与新生血管形成的关系。方法采用免疫组织化学法检测31例NSCLC组织和癌旁组织中EPO和EPO—R的表达情况，以21例肺良性病变组织作为对照，分析EPO和EPO—R表达与各临床病理因素的关系。以CD34标记血管内皮细胞，计算微血管密度（MVD）。结果EPO和EPO-R在NSCLC组织中的阳性率分别为67．7％和96．8％，在癌旁组织中阳性率分别为19．4％和35．5％，在肺良性病变组织中的阳性率分别为9．5％和19．O％（P=0．000）。EPO和EPO—R表达与NSCLC患者的临床分期、病理类型、组织分化程度及淋巴结转移无关（P〉0．05）。31例NSCLC患者中，EPO阳性者的MVD为26．14±5．26，显著高于EPO阴性者（15．97±8．29；t=5．34，P〈0．001）；EPO—R阳性者的MVD为27．13±6．33，显著高于EPO—R阴性者（11．72±5．130；t=7．46，P〈0．1301）。MVD与NSCLC分化程度有关，高、中分化的NSCLC组织中MVD低于低分化者（P=0．025），MVD与NSCLC分期有关，临床分期越晚，MVD越高（P〈0．001）。结论EPO和EPO—R在NSCLC组织中高表达，可能参与了肿瘤的发生过程；EPO／EPO—R的表达与NSCLC血管生成程度及病情进展有关，可为临床诊断提供依据。

Objective Erythropoietin and erythropoietin receptor （EPO-R） are expressed in many kinds of tumors. The EPO/EPO-R signaling is involved in tumor cell proliferation, invasion and angiogenesis. The aim of this study was to detect the expression of EPO-R in non-small cell lung cancer （NSCLC） , and explore its correlation with angiogenesis. Methods The expression patterns of EPO and EPO-R in 31 cases of NSCLC tissues were detected by immunohistochemistry, and that in benign lung lesions of 21 patients as control. To analyze the correlation of EPO/EPO-R expression patterns and clinicopathological factors. CD34 was used to label the vascular endothelial cells and calculate the microvessel density （MVD）. Results The positive rates of EPO and EPO-R expression in NSCLC were 67.7% and 96.8% , respectively, significantly higher than those in the control ones. The positive rates of EPO and EPO-R expression in adjacent tissues were 19.4% and 35.5% , and in benign lesions were 9.5% and 19.0%, respectively （P 〈0. 001 ）. The expression patterns of EPO/EPO-R were not related with pTNM stage, histological type, histological grade and lymph node metastasis （P 〉 0.05 ）. Increased MVD was correlated with poor differentiation, lymph node metastasis, and advanced stage. Conclusions High expression of EPO/EPO-R in NSCLC patients suggest that they may be involved in tumorigenesis. EPO/ EPO-R expression and MVD are closely related, and they might be an endogenous stimulant of angiogenesis during the progression of non-small cell lung cancer. It may provide evidence for clinical diagnosis.